Application Note

Quantitation Of Retrovirus-Like Particles (RVLPs) In CHO Derived Products

Microscope pipette GettyImages-503258063

Within the biopharmaceutical industry it is well recognized that Chinese Hamster Ovary (CHO) cells are the most commonly used production cell line for monoclonal antibodies and other recombinant proteins. Products derived from these cells have a very good safety record; there is no recorded incidence of patient infection from contaminants in a product manufactured from these cells. This is one of the reasons that CHO cells have been the cell substrate of choice for monoclonal antibody and other recombinant protein product development.

During the production of therapeutic proteins, CHO cells express endogenous retrovirus like particles (RVLPs) which must be removed during product purification. Once the manufacturing process has been scaled up and ready for commercialization, it is recommended that RVLPs be quantitated in the unprocessed bulk harvest material. Data from at least three lots of bulk harvest are required for submission to the regulatory authorities. This technical note will provide the scientific and regulatory landscape for key methods which are applied to ensure safety of such recombinant proteins, with a focus on alternate and superior methods to the standard transmission electron microscopy (TEM) method.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma